
SOC Encorafenib/Binimetinib Sets a Precedent for Therapeutic Improvements in BRAF V600E–Mutant NSCLC
Within the past 3 years, the BRAF V600E–mutant NSCLC treatment arsenal has seen positive shifts toward improved standards of care [SOC] following the FDA approvals of dabrafenib plus trametinib and encorafenib plus binimetinib, according to Joseph C. …